Item 1. Financial Statements
ACETO CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per-share amounts)
|
|
September 30,
2017
|
|
|
June 30,
2017
|
|
|
|
(unaudited)
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
72,100
|
|
|
$
|
55,680
|
|
Investments
|
|
|
3,048
|
|
|
|
2,046
|
|
Trade receivables, less allowance for doubtful accounts (September 30,
2017, $476; June 30, 2017, $485)
|
|
|
240,620
|
|
|
|
260,889
|
|
Other receivables
|
|
|
11,897
|
|
|
|
12,066
|
|
Inventory
|
|
|
135,119
|
|
|
|
136,387
|
|
Prepaid expenses and other current assets
|
|
|
4,916
|
|
|
|
3,941
|
|
Deferred income tax asset, net
|
|
|
-
|
|
|
|
546
|
|
Total current assets
|
|
|
467,700
|
|
|
|
471,555
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
11,569
|
|
|
|
10,428
|
|
Property held for sale
|
|
|
6,250
|
|
|
|
7,152
|
|
Goodwill
|
|
|
237,004
|
|
|
|
236,970
|
|
Intangible assets, net
|
|
|
277,247
|
|
|
|
285,081
|
|
Deferred income tax asset, net
|
|
|
10,991
|
|
|
|
19,453
|
|
Other assets
|
|
|
7,212
|
|
|
|
7,546
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
1,017,973
|
|
|
$
|
1,038,185
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Current portion of long-term debt
|
|
$
|
14,482
|
|
|
$
|
14,466
|
|
Accounts payable
|
|
|
98,013
|
|
|
|
90,011
|
|
Accrued expenses
|
|
|
114,654
|
|
|
|
118,328
|
|
Total current liabilities
|
|
|
227,149
|
|
|
|
222,805
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, net
|
|
|
317,097
|
|
|
|
339,200
|
|
Long-term liabilities
|
|
|
62,743
|
|
|
|
61,449
|
|
Environmental remediation liability
|
|
|
1,754
|
|
|
|
2,339
|
|
Deferred income tax liability
|
|
|
-
|
|
|
|
7,325
|
|
Total liabilities
|
|
|
608,743
|
|
|
|
633,118
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity:
|
|
|
|
|
|
|
|
|
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Common stock, $.01 par value, 75,000 shares authorized; 30,581 and 30,094 shares issued and outstanding at September 30, 2017 and June 30, 2017, respectively
|
|
|
306
|
|
|
|
301
|
|
Capital in excess of par value
|
|
|
217,439
|
|
|
|
214,198
|
|
Retained earnings
|
|
|
194,171
|
|
|
|
195,680
|
|
Accumulated other comprehensive loss
|
|
|
(2,686
|
)
|
|
|
(5,112
|
)
|
Total shareholders’ equity
|
|
|
409,230
|
|
|
|
405,067
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
$
|
1,017,973
|
|
|
$
|
1,038,185
|
|
See accompanying notes to condensed consolidated financial statements
and accountants’ review report.
ACETO CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME
(unaudited and in thousands, except per-share
amounts)
|
|
Three months Ended
September 30
|
|
|
|
2017
|
|
|
2016
|
|
Net sales
|
|
$
|
185,255
|
|
|
$
|
128,018
|
|
Cost of sales
|
|
|
145,272
|
|
|
|
97,179
|
|
Gross profit
|
|
|
39,983
|
|
|
|
30,839
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
31,149
|
|
|
|
21,024
|
|
Research and development expenses
|
|
|
1,615
|
|
|
|
1,050
|
|
Operating income
|
|
|
7,219
|
|
|
|
8,765
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income:
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(5,355
|
)
|
|
|
(2,233
|
)
|
Interest and other income, net
|
|
|
274
|
|
|
|
248
|
|
|
|
|
(5,081
|
)
|
|
|
(1,985
|
)
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
2,138
|
|
|
|
6,780
|
|
Income tax provision
|
|
|
1,684
|
|
|
|
2,395
|
|
Net income
|
|
$
|
454
|
|
|
$
|
4,385
|
|
|
|
|
|
|
|
|
|
|
Basic income per common share
|
|
$
|
0.01
|
|
|
$
|
0.15
|
|
Diluted income per common share
|
|
$
|
0.01
|
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
|
|
|
34,975
|
|
|
|
29,518
|
|
Diluted
|
|
|
35,259
|
|
|
|
29,840
|
|
See accompanying notes to condensed consolidated financial statements
and accountants’ review report.
ACETO CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
COMPREHENSIVE INCOME
(unaudited and in thousands)
|
|
Three months Ended
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
454
|
|
|
$
|
4,385
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments
|
|
|
2,320
|
|
|
|
560
|
|
Change in fair value of interest rate swaps
|
|
|
106
|
|
|
|
-
|
|
Comprehensive income
|
|
$
|
2,880
|
|
|
$
|
4,945
|
|
See accompanying notes to condensed consolidated financial statements
and accountants’ review report.
ACETO CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS
(unaudited and in thousands)
|
|
Three months Ended
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
Operating activities:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
454
|
|
|
$
|
4,385
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
8,301
|
|
|
|
3,168
|
|
Amortization of debt issuance costs and debt discount
|
|
|
1,513
|
|
|
|
1,432
|
|
Amortization of deferred financing costs
|
|
|
270
|
|
|
|
-
|
|
Provision for doubtful accounts
|
|
|
(15
|
)
|
|
|
(58
|
)
|
Non-cash stock compensation
|
|
|
3,146
|
|
|
|
1,664
|
|
Deferred income taxes
|
|
|
(1,099
|
)
|
|
|
1,405
|
|
Environmental charge
|
|
|
902
|
|
|
|
170
|
|
Earnings on equity investment in joint venture
|
|
|
(231
|
)
|
|
|
(325
|
)
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
Trade accounts receivable
|
|
|
21,137
|
|
|
|
9,141
|
|
Other receivables
|
|
|
149
|
|
|
|
464
|
|
Inventory
|
|
|
2,225
|
|
|
|
(6,105
|
)
|
Prepaid expenses and other current assets
|
|
|
(944
|
)
|
|
|
(978
|
)
|
Other assets
|
|
|
(334
|
)
|
|
|
(305
|
)
|
Accounts payable
|
|
|
7,699
|
|
|
|
3,135
|
|
Accrued expenses and other liabilities
|
|
|
792
|
|
|
|
(6,543
|
)
|
Net cash provided by operating activities
|
|
|
43,965
|
|
|
|
10,650
|
|
|
|
|
|
|
|
|
|
|
Investing activities:
|
|
|
|
|
|
|
|
|
Purchases of investments
|
|
|
(2,655
|
)
|
|
|
(1,017
|
)
|
Sales of investments
|
|
|
1,646
|
|
|
|
-
|
|
Payments for intangible assets
|
|
|
(54
|
)
|
|
|
(1,594
|
)
|
Purchases of property and equipment, net
|
|
|
(1,506
|
)
|
|
|
(541
|
)
|
Net cash used in investing activities
|
|
|
(2,569
|
)
|
|
|
(3,152
|
)
|
|
|
|
|
|
|
|
|
|
Financing activities:
|
|
|
|
|
|
|
|
|
Payment of cash dividends
|
|
|
(1,935
|
)
|
|
|
(1,954
|
)
|
Proceeds from exercise of stock options
|
|
|
73
|
|
|
|
185
|
|
Excess tax benefit on stock option exercises and restricted stock
|
|
|
-
|
|
|
|
437
|
|
Repayment of bank loans
|
|
|
(23,783
|
)
|
|
|
(49
|
)
|
Net cash used in financing activities
|
|
|
(25,645
|
)
|
|
|
(1,381
|
)
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash
|
|
|
669
|
|
|
|
197
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash
|
|
|
16,420
|
|
|
|
6,314
|
|
Cash and cash equivalents at beginning of period
|
|
|
55,680
|
|
|
|
66,828
|
|
Cash and cash equivalents at end of period
|
|
$
|
72,100
|
|
|
$
|
73,142
|
|
See accompanying notes to condensed consolidated financial statements
and accountants’ review report
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
(1) Basis of Presentation
The condensed consolidated financial statements
of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by
the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial
position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results
which may be achieved for the full year.
The preparation of financial statements
in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure
of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and
consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies
relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets;
long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.
These condensed consolidated financial
statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly,
these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained
in the Company’s Form 10-K for the year ended June 30, 2017.
(2) Business Combinations
On December 21, 2016, wholly owned subsidiaries
of Rising Pharmaceuticals, Inc. (“Rising”), a wholly owned subsidiary of Aceto, completed the acquisition of certain
generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”) and its affiliate Lucid
Pharma LLC (“Lucid”). Citron was a privately-held New Jersey-based pharmaceutical company focused on developing and
marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the
United States. Lucid was a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective
products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency.
Lucid serviced 18 national contracts with the Federal Government, nearly all of which have 5-year terms.
Aceto and Citron possess complementary
asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes consistent
with its strategy of expanding Rising’s portfolio of finished dosage form generic products through product development partnerships
and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses,
this transaction significantly expanded its roster of commercialized products and pipeline of products under development. In addition,
the Company believes that this product acquisition greatly enhanced its size and stature within the generic pharmaceutical industry,
expanded its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.
At closing, Aceto paid the sellers $270,000
in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers
on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase
agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial
performance of four pre-specified pipeline products that are currently in development. As of September 30, 2017, the Company accrued
$2,924 related to this contingent consideration.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
Rising formed two subsidiaries to consummate
the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health,
LLC (which acquired certain products and related assets of Lucid).
(3) Stock-Based Compensation
Under the Aceto Corporation 2015 Equity
Participation Plan (the “2015 Plan”), grants of stock options, stock appreciation rights, restricted stock, restricted
stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants
and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers.
The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015
Plan will not exceed, in the aggregate, 4,250 shares. Stock Awards that are intended to qualify as “performance-based compensation”
for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, may be granted. Performance-based awards
may be granted, vested and paid based on the attainment of specified performance goals.
Under the Aceto Corporation 2010 Equity
Participation Plan (as amended and restated in 2012, the “2010 Plan”), grants of stock options, restricted stock, restricted
stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the
Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010
Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in
lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock
(premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and
the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium
shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.
During the three months ended September
30, 2017, the Company granted 337 shares of restricted common stock to its employees that vest over three years. In addition,
the Company also issued a target grant of 168 performance-vested restricted stock units, which grant could be as much as 294 units
if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest
100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee
performance-vested restricted stock unit grant.
During the year ended June 30, 2017, the
Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common
stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying
vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units,
which grant could be as much as 280 if certain performance criteria and market conditions are met. These performance-vested restricted
stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth
in the applicable employee performance-vested restricted stock unit grant.
For the three months ended September 30,
2017 and 2016, the Company recorded stock-based compensation expense of approximately $3,132 and $1,659, respectively, related
to restricted common stock and restricted stock units. Included in the $3,132 for the three months ended September 30, 2017 is
$2,017 in stock-based compensation expense associated with the
separation of the Company’s former
Chief Executive Officer
in September 2017. As of September 30, 2017, the total unrecognized stock-based compensation cost
is approximately $10,168.
(4) Capital Stock
On August 24, 2017, the Company's
Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on September 21, 2017 to
shareholders of record as of September 8, 2017.
On May 4, 2017, the Board of Directors
of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock
repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions,
at prices not to exceed the market value of the common stock at the time of such purchase.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
The Company is authorized to issue 75,000
shares of Common Stock and 2,000 shares of Preferred Stock. The Board of Directors has authority under the Company’s Restated
Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board
of Directors.
(5) Net Income Per Common Share
Basic income per common share is based
on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive
effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding
and diluted weighted average shares outstanding:
|
|
Three Months Ended
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
|
|
|
34,975
|
|
|
|
29,518
|
|
Dilutive effect of stock options and restricted stock awards and units
|
|
|
284
|
|
|
|
322
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted average shares outstanding
|
|
|
35,259
|
|
|
|
29,840
|
|
The weighted average shares outstanding
for the three months ended September 30, 2017 includes the effect of 5,122 shares to be issued in connection with the acquisition
of certain products and related assets from Citron and Lucid (see Note 2).The Convertible Senior Notes (see Note 6) will only be
included in the dilutive net income per share calculations using the treasury stock method during periods in which the average
market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215
per share, and the impact would not be anti-dilutive.
There were 61 common equivalent shares
outstanding as of September 30, 2017 that were not included in the calculation of diluted net income per common share for the three
months ended September 30, 2017 because their effect would have been anti-dilutive.
(6) Debt
Long-term debt
|
|
September 30,
2017
|
|
|
June 30,
2017
|
|
|
|
|
|
|
|
|
Convertible Senior Notes, net
|
|
$
|
123,189
|
|
|
$
|
121,676
|
|
Revolving Bank Loans
|
|
|
70,000
|
|
|
|
90,000
|
|
Term Bank Loans
|
|
|
135,660
|
|
|
|
139,227
|
|
Mortgage
|
|
|
2,730
|
|
|
|
2,763
|
|
|
|
|
331,579
|
|
|
|
353,666
|
|
Less current portion
|
|
|
14,482
|
|
|
|
14,466
|
|
|
|
$
|
317,097
|
|
|
$
|
339,200
|
|
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
Convertible Senior Notes
In November 2015, Aceto offered $125,000
aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional
buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for
the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’
option to purchase additional Notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate
principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated
indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior
in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness
and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s
subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s
election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The
Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes
are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.
Holders may convert all or any portion
of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business
on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and
only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or
not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar
quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive
business day period after any five consecutive trading day period (which is referred to as the “measurement period”)
in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was
less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such
trading day; or (iii) upon the occurrence of specified corporate events.
Upon conversion
by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof.
As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as
a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash
interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional
non-cash interest expense.
The Company presents debt issuance costs as a direct deduction from the carrying value of the
debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.
In connection
with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties,
which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce
the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the
principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions
with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market
price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants
exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company
issued convertible debt and a freestanding “call-spread.”
The carrying value
of the Notes is as follows:
|
|
September 30,
2017
|
|
|
June 30,
2017
|
|
|
|
|
|
|
|
|
Principal amount
|
|
$
|
143,750
|
|
|
$
|
143,750
|
|
Unamortized debt discount
|
|
|
(17,951
|
)
|
|
|
(19,255
|
)
|
Unamortized debt issuance costs
|
|
|
(2,610
|
)
|
|
|
(2,819
|
)
|
Net carrying value
|
|
$
|
123,189
|
|
|
$
|
121,676
|
|
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
The following
table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying consolidated
statements of income for the three months ended September 30:
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
Contractual coupon
|
|
$
|
709
|
|
|
$
|
725
|
|
Amortization of debt discount
|
|
|
1,304
|
|
|
|
1,223
|
|
Amortization of debt issuance costs
|
|
|
209
|
|
|
|
209
|
|
|
|
$
|
2,222
|
|
|
$
|
2,157
|
|
Credit Facilities
On December 21, 2016 the Company entered
into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended
and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No.
1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement,
dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increases
the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available
revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company
may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”)
provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the
“2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible
Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit
Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of September
30, 2017, the Company borrowed Revolving Loans aggregating $70,000 which loans are Eurodollar Loans at interest rates ranging from
3.24% to 3.45 % at September 30, 2017. The applicable interest rate margin percentage is subject to adjustment quarterly based
upon the Company’s senior secured net leverage ratio.
Under the A&R Credit Agreement, the
Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining
commitments from existing or prospective lenders, the Company will have the right to increase the amount of the Initial Revolving
Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving
Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature
in the A&R Credit Agreement. As of September 30, 2017, the remaining amount outstanding under the Initial Term Loan is $138,750
and is payable as a Eurodollar Loan at an interest rate of 3.33%. The proceeds of the Initial Revolving Commitment and Initial
Term Loan have been used to partially finance the acquisition of generic products and related assets of Citron and its affiliate
Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly
based upon the Company’s senior secured net leverage ratio.
The Initial Term Loan is payable as to
principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue
on each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the
Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid
principal amount of the Initial Term Loan.
As such, the Company has classified $15,000
of the Initial Term Loan as short-term in the consolidated balance sheet at September 30, 2017. The A&R Credit Agreement, similar
to the First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment
mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had
no open letters of credit at September 30, 2017 and June 30, 2017.
In accordance with generally accepted accounting
principles, deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying
value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition,
deferred financing costs associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
The A&R Credit Agreement, like the
First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and
certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining
a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries
are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness,
limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The
Company was in compliance with all covenants at September 30, 2017.
Mortgage
On June 30, 2011, the Company entered into
a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage payable is secured by
the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013,
bears interest at 4.92% per annum as of September 30, 2017 and matures on June 30, 2021.
(7) Commitments, Contingencies and Other Matters
The Company and its subsidiaries are subject
to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when
a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide
an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly
basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not
probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined
that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements,
other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.
In fiscal years 2011, 2009, 2008 and 2007,
the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working
with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group
has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative
proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has
begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate
the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years
ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly
contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site
contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate
outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.
The Company has environmental remediation
obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals
located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the
contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating
that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of September 30,
2017 and June 30, 2017, a liability of $7,866 and $8,451, respectively, is included in the accompanying consolidated balance sheets
for this matter. For the three months ended September 30, 2017, the Company recorded an environmental charge of $902, which is
included in selling, general and administrative expenses in the accompanying condensed consolidated statement of income for the
three months ended September 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate
the site will be capitalized in preparing the property which is currently classified as held for sale. An estimate of the fair
value of the property has been determined by a third party real estate professional and supports the assumption that the expected
fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in
a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial
condition, operating results and cash flows when resolved in a future reporting period.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
In connection with the environmental remediation
obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the
former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation
costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past
response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550
in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously
expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing
its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of September
30, 2017 and June 30, 2017 is $3,540 and $3,803, respectively, which is included in the accompanying consolidated balance sheets.
In March 2006, Arsynco received notice
from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for
a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential
liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable
for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation
may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In
July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent
to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development
and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may
assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State
(or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with
respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with
that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the
former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had
previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et
al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding.
Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would
not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation;
(2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability
allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against
Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco
to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined
that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these
potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular
reporting period is not currently known.
A subsidiary of the Company markets certain
agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires
that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires
that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data
on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However,
when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product,
often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is
presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection
with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United
States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition
of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments
to various task force groups could approximate $2,357 through the next twelve months.
(8) Fair Value Measurements
GAAP defines fair value as the price that
would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement
date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions
based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three
levels:
Level 1 – Quoted market prices in active markets for identical
assets or liabilities;
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
Level 2 – Inputs other than Level 1 inputs that are either
directly or indirectly observable; and
Level 3 – Unobservable inputs that are not corroborated
by market data.
On a recurring basis, Aceto measures at
fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts.
The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level
1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities
publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued
interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign
currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and
payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges
and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s
foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable
futures foreign exchange rates. At September 30, 2017, the Company had foreign currency contracts outstanding that had a notional
amount of $48,816. Unrealized gains (losses) on hedging activities for the three months ended September 30, 2017 and 2016, was
$295 and ($36), respectively, and are included in interest and other income, net, in the consolidated statements of income. The
contracts have varying maturities of less than one year.
In conjunction
with its existing credit agreement (see Note 6), the Company entered into an interest rate swap on March 21, 2017 for an additional
interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge
.
The
expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of September 30, 2017
is $92,500. The unrealized loss to date associated with this derivative, which is recorded in accumulated other comprehensive loss
in the consolidated balance sheet at September 30, 2017, is $475. Aceto’s interest rate swaps are classified within Level
2 as the fair value of this hedge is primarily based on observable interest rates.
At September 30, 2017, the Company had
$3,077 of contingent consideration, $2,924 of which related to the acquisition of certain products and related assets of Citron
and Lucid, which was completed in December 2016 (see Note 2) and $153 of contingent consideration related to a previously acquired
company in France. At September 30, 2016, the Company had $135 of contingent consideration related to a previously acquired company
in France. The contingent consideration was calculated using the present value of a probability weighted income approach.
During the fourth quarter of each year,
the Company evaluates goodwill for impairment at the reporting unit level using a market participant approach using Level 3 inputs.
Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment.
Long-lived assets and certain identifiable
intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. If it is determined such indicators are present and the review indicates that the assets
will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying
values are reduced to estimated fair value. Measurements based on undiscounted cash flows are considered to be Level
3 inputs.
In connection with the acquisition of certain
products and related assets of Citron and Lucid (see Note 2), the Company will issue 5,122 shares of Aceto common stock beginning
on December 21, 2019. The preliminary fair value of the future issuance of these shares was determined to be $90,400 at the time
of the product acquisition after taking into effect that the shares won’t be issued until the third and fourth anniversary
of the closing and the present value calculation of dividends.
In November 2015, the Company issued $143,750
aggregate principal amount of Notes (see Note 6). Since Aceto has the option to settle the potential conversion of the Notes in
cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately,
based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component
required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical
borrowing rate of 6.5%.
The value of the embedded conversion option was determined using an expected
present value technique (income approach) to estimate the fair value of similar non-convertible debt
and included utilization
of c
onvertible investors’ credit assumptions and high yield bond indices. The Notes approximate
a full fair value of $129,000 at September 30, 2017 giving effect to certain factors, including the term of the Notes, current
stock price of Aceto stock and effective interest rate.
The carrying values of all financial instruments
classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these
instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current
rates offered for similar financial instruments to the Company.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
The following tables summarize the valuation of the Company’s
financial assets and liabilities which were determined by using the following inputs at September 30, 2017 and June 30, 2017:
|
|
Fair Value Measurements at September 30, 2017 Using
|
|
|
|
Quoted Prices
in Active
Markets
(Level 1)
|
|
|
Significant
Other
Observable
Inputs (Level 2)
|
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Time deposits
|
|
|
-
|
|
|
$
|
5,970
|
|
|
|
-
|
|
|
$
|
5,970
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Time deposits
|
|
|
-
|
|
|
|
3,048
|
|
|
|
-
|
|
|
|
3,048
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts-assets (1)
|
|
|
-
|
|
|
|
529
|
|
|
|
-
|
|
|
|
529
|
|
Foreign currency contracts-liabilities (2)
|
|
|
-
|
|
|
|
232
|
|
|
|
-
|
|
|
|
232
|
|
Derivative liability for interest rate swap (3)
|
|
|
-
|
|
|
|
475
|
|
|
|
-
|
|
|
|
475
|
|
Contingent consideration (4)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
3,077
|
|
|
|
3,077
|
|
|
(1)
|
Included in “Other receivables” in the accompanying
Condensed Consolidated Balance Sheet as of September 30, 2017.
|
|
(2)
|
Included in “Accrued expenses” in the accompanying
Condensed Consolidated Balance Sheet as of September 30, 2017.
|
|
(3)
|
Included in “Long-term liabilities” in the
accompanying Condensed Consolidated Balance Sheet as of September 30, 2017.
|
|
(4)
|
$153 included in “Accrued expenses” and $2,924
included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2017.
|
|
|
Fair Value Measurements at June 30, 2017 Using
|
|
|
|
Quoted Prices
in Active
Markets
(Level 1)
|
|
|
Significant
Other
Observable
Inputs (Level 2)
|
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Time deposits
|
|
|
-
|
|
|
$
|
5,781
|
|
|
|
-
|
|
|
$
|
5,781
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Time deposits
|
|
|
-
|
|
|
|
2,046
|
|
|
|
-
|
|
|
|
2,046
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts-assets (5)
|
|
|
-
|
|
|
|
486
|
|
|
|
-
|
|
|
|
486
|
|
Foreign currency contracts-liabilities (6)
|
|
|
-
|
|
|
|
137
|
|
|
|
-
|
|
|
|
137
|
|
Derivative liability for interest rate swap(7)
|
|
|
-
|
|
|
|
581
|
|
|
|
-
|
|
|
|
581
|
|
Contingent consideration (8)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
2,952
|
|
|
|
2,952
|
|
|
(5)
|
Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
|
|
(6)
|
Included in “Accrued expenses” in the accompanying
Condensed Consolidated Balance Sheet as of June 30, 2017.
|
|
(7)
|
Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
|
|
(8)
|
$145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying
Condensed Consolidated Balance Sheet as of June 30, 2017.
|
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
(9) Recent Accounting Pronouncements
In August 2017, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-12,
Derivatives and Hedging
(Topic 815): Targeted Improvements to Accounting for Hedging Activities
which has the objective of improving the financial
reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its
financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify
the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business
entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted.
The Company is currently evaluating the impact of the provisions of ASU 2017-12.
In May 2017, the FASB issued ASU 2017-09,
Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting,
which provides guidance about which
changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718.
ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after
December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material
impact on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04
Intangibles - Goodwill and Other (Topic 350)
which would eliminate the requirement to calculate the implied fair value of
goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying
amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning
after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates
after January 1, 2017. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated
financial statements.
In January 2017, the FASB issued ASU 2017-01
Business Combinations (Topic 805): Clarifying the Definition of a Business
with the objective of adding guidance to assist
entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU
2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within
those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial
statements.
In August 2016, the FASB issued ASU 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,
which addresses eight specific
cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified
in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December
15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU
2016-15.
In March 2016, the FASB issued ASU 2016-09,
Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
, which changes certain
aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires
that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income
for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation
costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity
to the extent of previous windfalls and then to the statement of income. For the three months ended September 30, 2017, the Company
recorded $1,128 of additional income tax expense associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively
or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on
the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from
financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt
such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the
impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to
be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company
recognizes forfeitures when they actually occur.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842)
that replaces existing lease guidance. The new standard is intended to provide enhanced transparency
and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet.
The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of
expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within
those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.
In November 2015, the FASB issued ASU 2015-17,
Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets.
This ASU is intended to simplify the presentation
of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities
as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current
or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new
guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption
of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's
financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU
2015-17 has no impact on the Company's results of operations or cash flows.
In July 2015, the FASB issued ASU 2015-11,
Inventory (Topic 330)
–
Simplifying the Measurement of Inventory.
This ASU requires that an entity measure
inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal
years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard
in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial
statements of the Company.
In May 2014, the FASB issued ASU 2014-09,
Revenue from Contracts with Customers (Topic 606),
which is the new comprehensive revenue recognition standard that will
supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize
revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company
expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue
from Contracts with Customers - Deferral of the Effective Date, which approved a one year deferral of ASU 2014-09 for annual reporting
periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016,
the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross
versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively,
which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12,
Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in
practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition.
Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from
Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have
a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has
made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue
from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the
customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to
its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that
the timing of recognition of revenue will be substantially unchanged under the amended guidance. The Company is continuing to evaluate
the impact on certain other transactions including third-party collaborations and other arrangements. The amended guidance will
be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize
effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the
cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates
adopting this amended standard on a modified retrospective basis.
(10) Segment Information
The Company's business is organized along
product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.
Human Health
- includes finished
dosage form generic drugs and nutraceutical products.
ACETO CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited and in thousands, except per-share
amounts)
Pharmaceutical Ingredients –
includes
pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).
Performance Chemicals
- The Performance
Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals
include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels
and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries
such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.
Agricultural Protection Products include
herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms
that can severely damage plant growth.
The Company's chief operating decision
maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate
amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not
allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments'
performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker
has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments
into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the
following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class
of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e)
the nature of the regulatory environment.
Three months Ended September 30, 2017 and 2016:
|
|
Human
Health
|
|
|
Pharmaceutical
Ingredients
|
|
|
Performance
Chemicals
|
|
|
Unallocated
Corporate
|
|
|
Consolidated
Totals
|
|
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
106,015
|
|
|
$
|
36,576
|
|
|
$
|
42,664
|
|
|
$
|
-
|
|
|
$
|
185,255
|
|
Gross profit
|
|
|
24,647
|
|
|
|
5,840
|
|
|
|
9,496
|
|
|
|
-
|
|
|
|
39,983
|
|
Income (loss) before income taxes
|
|
|
5,026
|
|
|
|
2,231
|
|
|
|
4,945
|
|
|
|
(10,064
|
)
|
|
|
2,138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
47,889
|
|
|
$
|
40,616
|
|
|
$
|
39,513
|
|
|
$
|
-
|
|
|
$
|
128,018
|
|
Gross profit
|
|
|
14,205
|
|
|
|
6,954
|
|
|
|
9,680
|
|
|
|
-
|
|
|
|
30,839
|
|
Income (loss) before income taxes
|
|
|
3,972
|
|
|
|
3,067
|
|
|
|
4,832
|
|
|
|
(5,091
|
)
|
|
|
6,780
|
|
Report of Independent Registered Public
Accounting Firm
Board of Directors and Shareholders
Aceto Corporation
Port Washington, NY
We have reviewed the condensed consolidated
balance sheet of Aceto Corporation and subsidiaries as of September 30, 2017 and related condensed consolidated statements of income
and comprehensive income for the three-month periods ended September 30, 2017 and 2016, and cash flows for the three-month periods
ended September 30, 2017 and 2016 included in the accompanying Securities and Exchange Commission Form 10-Q for the period ended
September 30, 2017. These interim financial statements are the responsibility of the Company’s management.
We conducted our reviews in accordance
with standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists
principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters.
It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight
Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly,
we do not express such an opinion.
Based on our reviews, we are not aware
of any material modifications that should be made to the condensed consolidated financial statements referred to above for them
to be in conformity with accounting principles generally accepted in the United States of America.
We have previously audited, in accordance
with standards of the Public Company Accounting Oversight Board, the consolidated balance sheet of Aceto Corporation and subsidiaries
as of June 30, 2017, and the related consolidated statements of income, comprehensive income, shareholders’ equity and cash
flows for the year then ended (not presented herein); and in our report dated August 25, 2017, we expressed an unqualified opinion
on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated
balance sheet as of June 30, 2017, is fairly stated, in all material respects, in relation to the consolidated balance sheet from
which it has been derived.
/s/ BDO USA, LLP
|
|
|
|
Melville, New York
|
|
November 3, 2017
|
|
|
Item 2.
|
Management's Discussion and Analysis of Financial Condition
and Results of Operations
|
CAUTIONARY STATEMENT RELATING TO THE SAFE
HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This Quarterly Report contains forward-looking
statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained
in this Quarterly Report may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated
benefits or other consequences of our plans or strategies, financing plans, projected or anticipated benefits from acquisitions
that we may make, or projections involving anticipated revenues, earnings or other aspects of our operating results or financial
position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates
and projections of management. We intend for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking
statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,”
“project,” “plan,” “intend,” “estimate,” and “continue,” and their
opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are
not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of
which are beyond our control that may influence the accuracy of the statements and the projections upon which the statements are
based. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement
include, but are not limited to, our ability to remain competitive with competitors, risks associated with the generic product
industry, dependence on a limited number of suppliers, risks associated with healthcare reform and reductions in reimbursement
rates, difficulty in predicting revenue stream and gross profit, industry and market changes, the effect of fluctuations in operating
results on the trading price of our common stock, risks associated with holding a significant amount of debt, inventory levels,
reliance on outside manufacturers, risks of incurring uninsured environmental and other industry specific liabilities, governmental
approvals and regulations, risks associated with hazardous materials, potential violations of government regulations, product liability
claims, reliance on Chinese suppliers, potential changes to Chinese laws and regulations, potential changes to laws governing our
relationships in India, fluctuations in foreign currency exchange rates, tax assessments, changes in tax rules, global economic
risks, risk of unsuccessful acquisitions, effect of acquisitions on earnings, indemnification liabilities, terrorist activities,
reliance on key executives, litigation risks, volatility of the market price of our common stock, changes to estimates, judgments
and assumptions used in preparing financial statements, failure to maintain effective internal controls, and compliance with changing
regulations, as well as other risks and uncertainties discussed in our reports filed with the Securities and Exchange Commission,
including, but not limited to, our Annual Report on Form 10-K for the fiscal year ended June 30, 2017 and other filings. Copies
of these filings are available at www.sec.gov.
Any one or more of these uncertainties,
risks and other influences could materially affect our results of operations and whether forward-looking statements made by us
ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed
or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements,
whether from new information, future events or otherwise.
NOTE REGARDING DOLLAR AMOUNTS
In this quarterly report, all dollar amounts
are expressed in thousands, except for per-share amounts.
The following
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide the
readers of our financial statements with a narrative discussion about our business. The MD&A is provided as a supplement to
and should be read in conjunction with our financial statements and the accompanying notes.
Executive Summary
We are reporting net sales of $185,255
for the three months ended September 30, 2017, which represents a 44.7% increase from the $128,018 reported in the comparable prior
period. Gross profit for the three months ended September 30, 2017 was $39,983 and our gross margin was 21.6% as compared to gross
profit of $30,839 and gross margin of 24.1% in the comparable prior period. Our selling, general and administrative costs (“SG&A”)
for the three months ended September 30, 2017 was $31,149, an increase of $10,125 from what we reported in the prior period. Our
net income decreased to $454, or $0.01 per diluted share, compared to net income of $4,385, or $0.15 per diluted share, in the
prior period. As more fully described below, results for the quarter ended September 30, 2017 reflect the Company’s acquisition
in December 2016 of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”),
and its affiliate Lucid Pharma LLC (“Lucid”).
Our financial position as of September
30, 2017 remains strong, as we had cash and cash equivalents and short-term investments of $75,148, working capital of $240,551
and shareholders’ equity of $409,230.
Our business is separated into three principal
segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.
Products that fall within the Human Health
segment include finished dosage form generic drugs and nutraceutical products. Aceto sells generic prescription products and over-the-counter
pharmaceutical products to leading wholesalers, chain drug stores, distributors and mass merchandisers. On December 21, 2016, Rising
completed the acquisition of certain generic products and related assets of Citron and Lucid. Rising formed two subsidiaries to
consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and
Acetris Health, LLC (which acquired certain products and related assets of Lucid). Citron was a privately-held New Jersey-based
pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic
pharmaceutical manufacturers based in India and the U.S. Lucid was a privately-held New Jersey-based generic pharmaceutical distributor
specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration
and the Defense Logistics Agency. Lucid serviced 18 national contracts with the Federal Government, nearly all of which have 5-year
terms.
The assets acquired in this transaction
expand, complement, and strengthen our existing and future product offerings. In what has become a competitive generic drug business
environment, one key for long-term success is having an ever-growing commercial portfolio of generic products, a strong internal
drug development pipeline and capable, reliable manufacturing partners. This transaction adds significantly to the Rising business
platform in all three crucial areas. We believe that, consistent with our strategy of expanding our portfolio of finished dosage
form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications
(“ANDAs”) and complementary generic drug businesses, this product acquisition significantly expanded our roster of
commercialized products and pipeline of products under development. In addition, we believe that this transaction greatly enhanced
our size and stature within the generic pharmaceutical industry, expanded our partnership network and offers us opportunities to
realize meaningful cost and tax efficiencies, as well as representing an integral component of Aceto's continued strategy to become
a Human Health oriented company.
According
to a QuintilesIMS press release on May 5, 2017, growth in U.S. spending on prescription medicines fell in 2016 as competition intensified
among manufacturers, and payers ramped up efforts to limit price increases. According to the QuintilesIMS Institute study, “Drug
spending grew at a 4.8 percent pace in 2016 to $323 billion, less than half the rate of the previous two years, after adjusting
for off-invoice discounts and rebates. The surge of innovative medicine introductions paused in 2016, with fewer than half as many
new drugs launched than in 2014 and 2015. While the total use of medicines continued to climb—with total prescriptions dispensed
reaching 6.1 billion, up 3.3 percent over 2015 levels—the spike in new patients being treated for hepatitis C ebbed, which
contributed to the decline in spend. Net price increases—reflecting rebates and other price breaks from manufacturers—averaged
3.5 percent last year, up from 2.5 percent in 2015.”
Aceto supplies the raw materials used in
the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds and biochemicals
used in pharmaceutical and nutritional preparations.
The Pharmaceutical Ingredients segment
has two product groups: Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates.
We supply APIs to many of the major generic
drug companies, who we believe view Aceto as a valued partner in their effort to develop and market generic drugs. The process
of introducing a new API from pipeline to market spans a number of years and begins with Aceto partnering with a generic pharmaceutical
manufacturer and jointly selecting an API, several years before the expiration of a composition of matter patent, for future genericizing.
We then identify the appropriate supplier, and concurrently utilizing our global technical network, work to ensure they meet standards
of quality to comply with regulations. Our client, the generic pharmaceutical company, will submit the ANDA for U.S. Food and Drug
Administration (“FDA”) approval or European-equivalent approval. The introduction of the API to market occurs after
all the development testing has been completed and the ANDA or European-equivalent is approved and the patent expires or is deemed
invalid. Aceto, at all times, has a pipeline of APIs at various stages of development both in the United States and Europe. Additionally,
as the pressure to lower the overall cost of healthcare increases, Aceto has focused on, and works very closely with our customers
to develop new API opportunities to provide alternative, more economical, second-source options for existing generic drugs. By
leveraging our worldwide sourcing, regulatory and quality assurance capabilities, we provide to generic drug manufacturers an alternative,
economical source for existing API products.
Aceto has long been a supplier of pharmaceutical
intermediates, the complex chemical compounds that are the building blocks used in producing APIs. These are the critical components
of all drugs, whether they are already on the market or currently undergoing clinical trials. Faced with significant economic pressures
as well as ever-increasing regulatory barriers, the innovative drug companies look to Aceto as a source for high quality intermediates.
Aceto employs, on occasion, the same second
source strategy for our pharmaceutical intermediates business that we use in our API business. Historically, pharmaceutical manufacturers
have had one source for the intermediates needed to produce their products. Utilizing our global sourcing, regulatory support and
quality assurance network, Aceto works with the large, global pharmaceutical companies, sourcing lower cost, quality pharmaceutical
intermediates that will meet the same high level standards that their current commercial products adhere to.
The Performance Chemicals segment includes specialty chemicals
and agricultural protection products.
Aceto is a major supplier to many different
industrial segments providing chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles,
fuels and lubricants. The paint and coatings industry produces products that bring color, texture, and protection to houses, furniture,
packaging, paper, and durable goods. Many of today's coatings are eco-friendly, by allowing inks and coatings to be cured by ultraviolet
light instead of solvents, or allowing power coatings to be cured without solvents. These growing technologies are critical in
protecting and enhancing the world's ecology and Aceto is focused on supplying the specialty additives that make modern coating
techniques possible.
The chemistry that makes much of the modern
world possible is often done by building up simple molecules to sophisticated compounds in step-by-step chemical processes. The
products that are incorporated in each step are known as intermediates and they can be as varied as the end uses they serve, such
as crop protection products, dyes and pigments, textiles, fuel additives, electronics - essentially all things chemical.
Aceto provides various specialty chemicals
for the food, flavor, fragrance, paper and film industries. Aceto’s raw materials are also used in sophisticated technology
products, such as high-end electronic parts used for photo tooling, circuit boards, production of computer chips, and in the production
of many of today's modern gadgets.
According to an October 17, 2017 Federal Reserve Statistical
Release, in the third quarter of calendar year 2017, the index for consumer durables, which impacts the Specialty Chemicals business
of the Performance Chemicals segment, is expected to decrease at an annual rate of 6.4%.
Aceto’s agricultural protection products
include herbicides, fungicides and insecticides, which control weed growth as well as the spread of insects and microorganisms
that can severely damage plant growth. One of Aceto's most widely used agricultural protection products is a sprout inhibitor that
extends the storage life of potatoes. Utilizing our global sourcing and regulatory capabilities, we identify and qualify manufacturers
either producing the product or with knowledge of the chemistry necessary to produce the product, and then file an application
with the U.S. EPA for a product registration. Aceto has an ongoing working relationship with manufacturers in China and India to
determine which of the non-patented or generic, agricultural protection products they produce can be effectively marketed in the
Western world. We have successfully brought numerous products to market. We have a strong pipeline, which includes future additions
to our product portfolio. The combination of our global sourcing and regulatory capabilities makes the generic agricultural market
a niche for us and we will continue to offer new product additions in this market. In the National Agricultural Statistics Services
release dated June 30, 2017, the total crop acreage planted in the United States in 2017 decreased by .3% to 318 million acres
from 319 million acres in 2016. The number of peanut acres planted in 2017 increased 8.8% from 2016 levels while sugarcane acreage
harvested decreased 3.4% from 2016. In addition, the potato acreage harvested in 2017 increased approximately .7% from the 2016
level.
We believe our main business strengths
are sourcing, regulatory support, quality assurance, marketing and distribution. We distribute more than 1,100 chemical compounds
used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial
chemical industries. With business operations in ten countries, we believe that our global reach is distinctive in the industry,
enabling us to source and supply quality products on a worldwide basis. Leveraging local professionals, we source approximately
two-thirds of our products from Asia, buying from approximately 500 companies in China and 200 in India.
In this MD&A, we explain our general
financial condition and results of operations, including, among other things, the following:
|
·
|
factors that affect our business
|
|
·
|
our earnings and costs in the periods presented
|
|
·
|
changes in earnings and costs between periods
|
|
·
|
the impact of these factors on our overall financial condition
|
As you read this MD&A section, refer
to the accompanying condensed consolidated statements of income, which present the results of our operations for the three months
ended September 30, 2017 and 2016. We analyze and explain the differences between periods in the specific line items of the condensed
consolidated statements of income.
Critical Accounting Estimates and
Policies
As disclosed in our Form 10-K for the year
ended June 30, 2017, the discussion and analysis of our financial condition and results of operations is based on our consolidated
financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. In preparing these
financial statements, we were required to make estimates and assumptions that affect the amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. We regularly evaluate our estimates including those
related to allowances for bad debts, revenue recognition, partnered products, inventories, goodwill and indefinite-life intangible
assets, long-lived assets, environmental and other contingencies, income taxes, stock-based compensation and purchase price allocation.
We base our estimates on various factors, including historical experience, advice from outside subject-matter experts, and various
assumptions that we believe to be reasonable under the circumstances, which together form the basis for our making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates. Since June 30, 2017, there have been no significant changes to the assumptions and estimates related to those
critical accounting estimates and policies.
RESULTS OF OPERATIONS
Three Months Ended September 30, 2017 Compared to Three Months
Ended September 30, 2016
|
|
Net Sales by Segment
Three months ended September 30,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
|
2016
|
|
|
Comparison
2017
Over/(Under) 2016
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
$
|
|
|
%
|
|
Segment
|
|
Net sales
|
|
|
Total
|
|
|
Net sales
|
|
|
Total
|
|
|
Change
|
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Human Health
|
|
$
|
106,015
|
|
|
|
57.2
|
%
|
|
$
|
47,889
|
|
|
|
37.4
|
%
|
|
$
|
58,126
|
|
|
|
121.4
|
%
|
Pharmaceutical Ingredients
|
|
|
36,576
|
|
|
|
19.8
|
|
|
|
40,616
|
|
|
|
31.7
|
|
|
|
(4,040
|
)
|
|
|
(9.9
|
)
|
Performance Chemicals
|
|
|
42,664
|
|
|
|
23.0
|
|
|
|
39,513
|
|
|
|
30.9
|
|
|
|
3,151
|
|
|
|
8.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
185,255
|
|
|
|
100.0
|
%
|
|
$
|
128,018
|
|
|
|
100.0
|
%
|
|
$
|
57,237
|
|
|
|
44.7
|
%
|
|
|
Gross Profit by Segment
Three months ended September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
Comparison 2017
Over/(Under) 2016
|
|
|
|
Gross
|
|
|
% of
|
|
|
Gross
|
|
|
% of
|
|
|
$
|
|
|
%
|
|
Segment
|
|
Profit
|
|
|
Sales
|
|
|
Profit
|
|
|
Sales
|
|
|
Change
|
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Human Health
|
|
$
|
24,647
|
|
|
|
23.2
|
%
|
|
$
|
14,205
|
|
|
|
29.7
|
%
|
|
$
|
10,442
|
|
|
|
73.5
|
%
|
Pharmaceutical Ingredients
|
|
|
5,840
|
|
|
|
16.0
|
|
|
|
6,954
|
|
|
|
17.1
|
|
|
|
(1,114
|
)
|
|
|
(16.0
|
)
|
Performance Chemicals
|
|
|
9,496
|
|
|
|
22.3
|
|
|
|
9,680
|
|
|
|
24.5
|
|
|
|
(184
|
)
|
|
|
(1.9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
$
|
39,983
|
|
|
|
21.6
|
%
|
|
$
|
30,839
|
|
|
|
24.1
|
%
|
|
$
|
9,144
|
|
|
|
29.7
|
%
|
Net Sales
Net sales increased $57,237, or 44.7%,
to $185,255 for the three months ended September 30, 2017, compared with $128,018 for the prior period. We reported sales increases
in our Human Health and Performance Chemicals segments and a decrease in our Pharmaceutical Ingredients segment.
Human Health
Net sales for the Human Health segment
increased by $58,126 for the three months ended September 30, 2017, to $106,015, which represents a 121.4% increase over net sales
of $47,889 for the prior period. The primary reason for the increase is due to the acquisition of certain products and related
assets of Citron and Lucid. Sales from the product acquisition of $55,130 are included in the three months ended September 30,
2017.
Pharmaceutical Ingredients
Net sales for the Pharmaceutical Ingredients
segment decreased $4,040 or 9.9% to $36,576 when compared to the prior period net sales of $40,616. The decrease in sales for this
segment was due primarily to a decline in sales of domestic APIs of $2,792, mainly due to reduced orders of a customer-launched
API, as well as a drop in customer demand for two other API products, sold in the U.S. Domestic sales of intermediates have decreased
$1,036 from the prior period due to customer inventory reduction and a delay in timing of orders for certain intermediate products.
Performance Chemicals
Net sales for the Performance Chemicals
segment was $42,664 for the three months ended September 30, 2017, representing an increase of $3,151 or 8.0%, from net sales of
$39,513 for the prior period. Specialty Chemicals business experienced a rise in sales of $4,251 over the prior period. The rise
in Specialty Chemicals sales is partly due to an increase in domestic sales of $1,658, primarily from increased sales of agricultural
and pigment intermediates. In addition, sales of specialty chemical products sold abroad, increased $2,593 over the prior period,
predominantly at our subsidiaries in France and Germany. Performance Chemicals sales were impacted by a $1,100 drop in sales of
our agricultural protection products, predominantly from a decline in sales of a fungicide used to prevent disease on pecan crops,
which we expect to sell in our second quarter of fiscal year 2018.
Gross Profit
Gross profit increased $9,144 to $39,983
(21.6% of net sales) for the three months ended September 30, 2017, as compared to $30,839 (24.1% of net sales) for the prior period.
Human Health
Human Health segment’s gross profit
of $24,647 for the three months ended September 30, 2017 increased $10,442, or 73.5%, over the prior period. The gross margin of
23.2% was lower than the prior period’s gross margin of 29.7%, but consistent with quarters subsequent to the product acquisition.
The increase in Human Health’s gross profit was partially related to gross profit of $11,332 on sales from the product acquisition,
which is included in the three months ended September 30, 2017. This increase was partially offset by the decline of gross profit
and gross margin on other Rising products, primarily driven by unfavorable product mix on certain products and increased competition.
Pharmaceutical Ingredients
Pharmaceutical Ingredients’ gross
profit of $5,840 for the three months ended September 30, 2017 decreased $1,114, or 16.0%, over the prior period. The gross margin
of 16.0% was lower than the prior period’s gross margin of 17.1%. The decrease in gross profit and gross margin was predominantly
the result of the decrease in the sales volume of APIs sold domestically, as well as a drop in reorders of a certain API which
typically yields a significantly higher gross margin. In addition, our international subsidiaries experienced an unfavorable product
mix on API sales.
Performance Chemicals
Gross profit for the Performance Chemicals
segment decreased to $9,496 for the three months ended September 30, 2017, versus $9,680 for the prior year, a decrease of $184
or 1.9%. The gross margin at 22.3% for the three months ended September 30, 2017 was lower than the prior year’s gross margin
of 24.5%. The decrease in gross profit was due to a $429 decline in gross profit for the Agricultural Protection Products business,
as a result of the sales volume decline. The drop in gross margin from the prior period is a result of an unfavorable product mix
on sales of specialty chemical products sold domestically.
Selling, General and Administrative Expenses
SG&A of $31,149 for the three months
ended September 30, 2017 increased $10,125 or 48.2% from $21,024 reported for the prior period. As a percentage of sales, SG&A
increased to 16.8% for the three months ended September 30, 2017 versus 16.4% in the prior period. SG&A for the current period
included $5,379
of amortization expense associated with the purchased intangible assets
related
to the product purchase
. We recorded $4,064 of one-time costs associated with the separation of the
Company’s former Chief Executive Officer, including $2,017 of stock-based compensation. In addition,
SG&A increased
due to a $902 environmental charge related to Arsynco. The increase in SG&A is also due in part to approximately $325 of consulting
services provided by former Citron and Lucid employees in connection with the Transition Services Agreement associated with the
product purchase agreement, as well as approximately $680 of outsourcing fees related to the accounting processes of Rising Health
and Acetris Health. SG&A for the prior period included $1,809 of transaction costs related to the product purchase agreement.
Research and Development Expenses
Research and development expenses (“R&D”)
increased to $1,615 for the three months ended September 30, 2017 compared to $1,050 for the prior period. R&D expenses represent
investment in our generic finished dosage form product pipeline. The majority of the R&D expenses are milestone based, which
was the primary cause for such increase and will likely cause fluctuation from quarter to quarter.
Operating Income
For the three months ended September 30,
2017 operating income was $7,219 compared to $8,765 in the prior period, a decrease of $1,546 or 17.6%.
Interest Expense
Interest expense was $5,355 for the three
months ended September 30 2017, an increase of $3,122 or 139.8% from the prior period. The increase was primarily due to
interest
expense associated with the Second Amended and Restated
Credit Agreement
, which was entered into
on December 21, 2016 to help fund our product acquisition, as well as additional interest associated with the
$50,000 unsecured
deferred payment
related to the product acquisition.
Provision for Income Taxes
The effective tax rate for the three months ended September
30, 2017 increased to 78.8% compared to 35.3% for the prior period. For the three months ended September 30, 2017, we recorded
$1,128 of additional income tax expense associated with net tax deficiencies under ASU 2016-09, which was adopted in the first
quarter of fiscal 2018.
Liquidity and Capital Resources
Cash Flows
At September 30, 2017, we had $72,100 in
cash, of which $47,050 was outside the United States, $3,048 in short-term investments, all of which is held outside the United
States, and $331,579 in long-term debt (including the current portion), all of which is an obligation in the United States. Working
capital was $240,551 at September 30, 2017 compared to $248,750 at June 30, 2017. The $47,050 of cash held outside of the United
States is fully accessible to meet any liquidity needs of our business located in any of the countries in which we operate. The
majority of the cash located outside of the United States is held by our European operations and can be transferred into the United
States. Although these amounts are fully accessible, transferring these amounts into the United States or any other countries could
have certain tax consequences. We intend to indefinitely reinvest these undistributed earnings and have no plan for further repatriation.
A deferred tax liability will be recognized when we expect that we will recover undistributed earnings of our foreign subsidiaries
in a taxable manner, such as through receipt of dividends or sale of the investments. A portion of our cash is held in operating
accounts that are with third party financial institutions. While we monitor daily the cash balances in our operating accounts and
adjust the cash balances as appropriate, these cash balances could be impacted if the underlying financial institutions fail or
are subject to other adverse conditions in the financial markets. To date, we have experienced no loss or lack of access to cash
in our operating accounts.
Our cash position at September 30, 2017
increased $16,420 from the amount at June 30, 2017.
Operating activities for the three months
ended September 30, 2017 provided cash of $43,965 for this period, as compared to cash provided of $10,650 for the comparable period.
The $43,965 resulted from $454 in net income and $12,787 derived from adjustments for non-cash items and a net $30,724 increase
from changes in operating assets and liabilities. The non-cash items included $8,301 in depreciation and amortization expense,
$1,099 for deferred income taxes, a $902 environmental charge, $1,513 for amortization of debt issuance costs and debt discount
and $3,146 in non-cash stock compensation expense. Trade accounts receivable decreased $21,137 during the three months ended September
30, 2017, due predominantly to a decrease in days sales outstanding, particularly at our Rising subsidiary. Inventories decreased
by $2,225 and accounts payable increased by $7,699 due primarily to inventories held in stock at our Rising subsidiary, as well
as timing of payments processed at the end of the quarter. Our cash position at September 30, 2016 increased $6,314 from the amount
at June 30, 2016. Operating activities for the three months ended September 30, 2016 provided cash of $10,650 for this period.
The $10,650 resulted from $4,385 in net income and $7,456 derived from net adjustments for non-cash items less a net $1,191 decrease
from changes in operating assets and liabilities.
Investing activities for the three months
ended September 30, 2017 used cash of $2,569 primarily from purchases of property and equipment and intangible assets of $1,560
and purchases of investments in time deposits of $2,655, offset by sales of investments in time deposits of $1,646. Investing activities
for the three months ended September 30, 2016 used cash of $3,152 primarily from purchases of intangible assets and property and
equipment of $2,135 and purchases of investments in time deposits of $1,017.
Financing activities for the three months
ended September 30, 2017 used cash of $25,645, primarily from $23,783 of repayments of bank loans and $1,935 payment of cash dividends.
Financing activities for the three months ended September 30, 2016 used cash of $1,381 primarily from $1,954 payment of cash dividends
offset in part by $437 of excess income tax benefits on stock option exercises.
Credit Facilities
We have available credit facilities with
certain foreign financial institutions. At September 30, 2017, the Company had available lines of credit with foreign financial
institutions totaling $7,602, all of which is available for borrowing by the respective foreign territories. We are not subject
to any financial covenants under these arrangements.
On December 21, 2016 the Company entered
into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended
and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No.
1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement,
dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increases
the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available
revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company
may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”)
provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the
“2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible
Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit
Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of September
30, 2017, the Company borrowed Revolving Loans aggregating $70,000 which loans are Eurodollar Loans at interest rates ranging from
3.24% to 3.45 % at September 30, 2017. The applicable interest rate margin percentage is subject to adjustment quarterly based
upon the Company’s senior secured net leverage ratio.
Under the A&R Credit Agreement, the
Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining
commitments from existing or prospective lenders, the Company will have the right to increase the amount of the Initial Revolving
Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving
Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature
in the A&R Credit Agreement. As of September 30, 2017, the remaining amount outstanding under the Initial Term Loan is $138,750
and is payable as a Eurodollar Loan at an interest rate of 3.33%. The proceeds of the Initial Revolving Commitment and Initial
Term Loan have been used to partially finance the acquisition of generic products and related assets of Citron and its affiliate
Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly
based upon the Company’s senior secured net leverage ratio.
The A&R Credit Agreement, similar to
Aceto’s First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary
payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company
had no open letters of credit at September 30, 2017 and June 30, 2017.
The A&R Credit Agreement, like the
First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and
certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining
a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries
are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness,
limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The
Company was in compliance with all covenants at September 30, 2017.
In conjunction with the Credit Agreement,
the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount
of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021.
The remaining balance of this derivative as of September 30, 2017 is $92,500.
Working Capital Outlook
Working capital was $240,551 at September
30, 2017 versus $248,750 at June 30, 2017. We continually evaluate possible acquisitions of, or investments in, businesses that
are complementary to our own, and such transactions may require the use of cash, as is the case with our recent product acquisition.
In connection with the acquisition of certain
products and related assets from Citron and Lucid, Aceto committed to make a $50,000 unsecured deferred payment that will bear
interest at a rate of 5% per annum to the sellers on December 21, 2021 and to issue 5,122 shares of Aceto common stock beginning
on December 21, 2019. The product purchase agreement also provides for a 5-year potential earn-out of up to an additional $50,000
in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of September
30, 2017, the Company accrued $2,924 related to this contingent consideration.
In October 2015, we filed a universal shelf
registration statement with the SEC to allow us to potentially offer an indeterminate principal amount and number of securities
in the future with a proposed maximum aggregate offering price of up to $200,000. Under the shelf registration statement, we have
the flexibility to publicly offer and sell from time to time common stock, debt securities, preferred stock, warrants and units
or any combination of such securities.
In November 2015, we offered $125,000 aggregate
principal amount of 2% Convertible Senior Notes due 2020 in a private offering to qualified institutional buyers pursuant to Rule
144A under the Securities Act of 1933, as amended. In addition, we granted the initial purchasers for the offering an option to
purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional
notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate principal amount. The remaining
net proceeds received from the offering, after paying down our credit facilities and costs associated with the offering and a related
hedge transaction, have been or will be used for general corporate purposes, which may include funding research, development and
product manufacturing, acquisitions or investments in businesses, products or technologies that are complementary to Aceto’s
own, increasing working capital and funding capital expenditures.
In connection with our agricultural protection
business, we plan to continue to acquire product registrations and related data filed with the United States Environmental Protection
Agency as well as payments to various task force groups, which could approximate $2,357 over the next twelve months.
In connection with our environmental remediation
obligation for Arsynco, we anticipate paying $6,112 towards remediation of the property in the next twelve months, which is included
in accrued expenses in our Condensed Consolidated Balance Sheet as of September 30, 2017.
We believe that our cash, other liquid
assets, operating cash flows, borrowing capacity and access to the equity capital markets, taken together, provide adequate resources
to fund ongoing operating expenditures, the repayment of our bank loans and the anticipated continuation of cash dividends for
the next twelve months.
Impact of Recent Accounting Pronouncements
In August 2017, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-12,
Derivatives and Hedging
(Topic 815): Targeted Improvements to Accounting for Hedging Activities
which has the objective of improving the financial
reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its
financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify
the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business
entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted.
The Company is currently evaluating the impact of the provisions of ASU 2017-12.
In May 2017, the FASB issued ASU 2017-09,
Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting,
which provides guidance about which
changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718.
ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after
December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material
impact on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04
Intangibles - Goodwill and Other (Topic 350)
which would eliminate the requirement to calculate the implied fair value of
goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying
amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning
after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates
after January 1, 2017. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated
financial statements.
In January 2017, the FASB issued ASU 2017-01
Business Combinations (Topic 805): Clarifying the Definition of a Business
with the objective of adding guidance to assist
entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU
2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within
those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial
statements.
In August 2016, the FASB issued ASU 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,
which addresses eight specific
cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified
in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December
15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU
2016-15.
In March 2016, the FASB issued ASU 2016-09,
Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
, which changes certain
aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires
that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income
for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation
costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity
to the extent of previous windfalls and then to the statement of income. For the three months ended September 30, 2017, the Company
recorded $1,128 of additional income tax expense associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively
or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on
the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from
financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt
such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the
impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to
be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company
recognizes forfeitures when they actually occur.
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842)
that replaces existing lease guidance. The new standard is intended to provide enhanced transparency
and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet.
The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of
expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within
those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.
In November 2015, the FASB issued ASU 2015-17,
Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets.
This ASU is intended to simplify the presentation
of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities
as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current
or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new
guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption
of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's
financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU
2015-17 has no impact on the Company's results of operations or cash flows.
In July 2015, the FASB issued ASU 2015-11,
Inventory (Topic 330)
–
Simplifying the Measurement of Inventory.
This ASU requires that an entity measure
inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal
years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard
in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial
statements of the Company.
In May 2014, the FASB issued ASU 2014-09,
Revenue from Contracts with Customers (Topic 606),
which is the new comprehensive revenue recognition standard that will
supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize
revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company
expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue
from Contracts with Customers - Deferral of the Effective Date, which approved a one year deferral of ASU 2014-09 for annual reporting
periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016,
the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross
versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively,
which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12,
Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in
practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition.
Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from
Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have
a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has
made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue
from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the
customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to
its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that
the timing of recognition of revenue will be substantially unchanged under the amended guidance. The Company is continuing to evaluate
the impact on certain other transactions including third-party collaborations and other arrangements. The amended guidance will
be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize
effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the
cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates
adopting this amended standard on a modified retrospective basis.